Saturday 17 October 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22,375.6%, EPS grew 48.2% and free cash flow fell 9.01%, each against the same quarter a year earlier.
36.05
1.40
−3.74%
Follow SEPN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 18.62 | 4.17 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 28.99 | 30.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 75 | 130 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.35 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 1 | 46 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | 5 | (72) | (49) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 3,225.83 | (6,725.21) | (106.35) | |||||
| Net income | — | — | — | — | — | — | — | 4 | (72) | (49) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 1 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.08 | 0.11 | 1.04 | ||||
| Earnings | — | — | — | — | — | — | — | 2.17 | (7.26) | (1.10) | |||||
| Cash flow | — | — | — | — | — | — | — | (20.07) | (6.82) | 2.49 | |||||
| Capex | — | — | — | — | — | — | — | 11.47 | 2.07 | 0.27 | |||||
| Free cash flow | — | — | — | — | — | — | — | (8.61) | (4.75) | 2.76 | |||||
| Book value | — | — | — | — | — | — | — | (19.89) | 42.47 | 8.63 | |||||
| Shares, m | — | — | — | — | — | — | — | 2 | 10 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 58.37 | 210.70 | 26.85 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.54 | 3.23 | |||||
| EV/Sales | — | — | — | — | — | — | — | (87.31) | (115.74) | 18.34 | |||||
| EV/FCF | — | — | — | — | — | — | — | 2.21 | 2.65 | 6.90 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (39) | (67) | 110 | ||||
| Capex | — | — | — | — | — | — | — | 22 | 21 | 12 | |||||
| Free cash flow | — | — | — | — | — | — | — | (17) | (47) | 122 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 106 | 344 | 324 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (88) | (351) | (391) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (38) | 420 | 382 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (24.45) | (9.29) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (73.08) | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (37.62) | (12.19) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Septerna, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics, Inc. | $1.8B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| URGN Urogen Pharma | $1.8B | — (loss-making) | — (loss-making) | +199.22% (above 0%: growing) | n/m | +17.26% (above 0%: growing) | 90.93% | 0.15% | Compare |
| XNCR Xencor, Inc. | $1.8B | — (loss-making) | — (loss-making) | +17.46% (above 0%: growing) | n/m | −52.91% (below 0%: shrinking) | 100.00% | (72.37%) | Compare |
| VIR Vir Biotechnology, Inc. | $1.8B | — (loss-making) | — (loss-making) | +19,582.54% (above 0%: growing) | n/m | +200.47% (above 0%: growing) | 100.00% | 30.75% | Compare |
| SEPN Septerna, Inc. | $1.8B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | |
| BHVN Biohaven Ltd. | $1.7B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +49.13% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.7B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NUVB Nuvation Bio Inc. | $1.7B | — (loss-making) | — (loss-making) | +555.64% (above 0%: growing) | n/m | +10.62% (above 0%: growing) | 70.11% | (161.06%) | Compare |
| Median of peers | $1.8B | — | — | +131.43% | — | −21.14% | 80.52% | 0.00% |
Septerna, Inc. (SEPN) key facts
- Strength: Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Septerna, Inc. (SEPN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SEPN traded at $36.05, a market capitalization of $1.8 billion.
- Return on equity was −12.2% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.41 (safe zone) for fiscal 2025.